XSHE
300436
Market cap1.90bUSD
Oct 09, Last price
81.47CNY
1D
1.86%
1Q
-17.20%
Jan 2017
50.76%
IPO
170.39%
Name
Fujian Cosunter Pharmaceutical Co Ltd
Chart & performance
P/E
—
P/S
31.16
EPS
—
Div yield, %
—
Shrs. gr., 5y
2.56%
Rev. gr., 5y
2.47%
Revenues
416m
-5.68%
Net income
-218m
L+39.37%
CFO
-35m
L
Dividend
May 04, 20180.1 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 2001 and headquartered in Fuzhou, China, Fujian Cosunter Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the pharmaceutical industry. The company is actively involved in the full spectrum of pharmaceutical operations, encompassing the research and development, production, and sale of medicinal products across China. Its core offerings comprise Chinese patent medicines, which are utilized in treating a variety of conditions, including liver ailments, men's health (andrology), cardiovascular disorders, and other therapeutic areas.
Key people
Guoping Li
Chairman of the Board, General Manager · since 2020
Jianhui Guan
Chief Financial Officer · since 2017
Ke Hu
Chief Scientific Officer · since 2025
Yanru Hu
Deputy General Manager · since 2025
Bingxiang Zeng
Deputy General Manager
Qinghe Zhang
Deputy General Manager, Secretary of the Board · since 2023
Fuhu Huang
Chief Operating Officer, Director · since 2025
Guodong Li
Director · since 2024
Liqing Ye
Director
Chenming Zhuang
Deputy General Manager, Director · since 2024
Fengmin Lu
Independent Director · since 2024
Hongjun Wu
Independent Director · since 2024
Feimei Wu
Independent Director · since 2024
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||